Richard Haynes
Papers
1
Total Citations
12
H-Index
1
About
Richard Haynes is a leading clinical researcher in ophthalmology, whose work centers on innovative treatments for retinal diseases, particularly neovascular age-related macular degeneration (nAMD). His major contribution is the landmark STAR trial, a pivotal, randomised, double-masked, sham-controlled device study evaluating stereotactic radiotherapy as a novel approach to nAMD. This work demonstrated that ionising radiation can mitigate key pathogenic processes underlying the disease, offering a potential alternative or adjunct to the standard anti-VEGF injections. The STAR trial, published in 2024, has already garnered 12 citations, reflecting its immediate impact on the field. Haynes’ research addresses a critical unmet need—reducing the treatment burden of frequent intravitreal injections for patients with nAMD, a leading cause of blindness. His findings have reshaped discussions around non-invasive therapies, positioning him as a key figure in advancing ophthalmologic care. With a focus on translating mechanistic insights into practical, patient-centred solutions, Haynes continues to influence both clinical practice and future research directions in retinal disease management.
Research Focus
Key Achievements
Top Papers
- 1